You are currently viewing Moderna’s RSV Vaccine in Older Adults is 84% Effective

Moderna’s RSV Vaccine in Older Adults is 84% Effective

Moderna announced on Tuesday that its respiratory syncytial virus vaccine is effective in preventing disease in older adults.

According to the Boston biotech company, the vaccine was 83.7% effective in preventing lower respiratory tract disease, defined as two or more symptoms, in people aged 60 and older. It was effective at preventing lower respiratory tract disease with three or more symptoms in 82.4% of cases.

According to Moderna, no safety concerns have been identified during the vaccine’s clinical trial. According to the company, the trial’s safety and efficacy data will be published in a peer-reviewed journal. The clinical trial has enrolled approximately 37,000 people from 22 different countries.

Moderna stated that it intends to file an application for FDA approval in the first half of this year. There is currently no FDA-approved RSV vaccine.

In extended trading, Moderna’s stock rose nearly 7%.

According to the Centers for Disease Control and Prevention, RSV infections kill between 6,000 and 10,000 older people each year and cause 60,000 to 120,000 hospitalizations.

The United States experienced an unusually severe RSV season in the fall, particularly among children and the elderly, as the public largely abandoned public health measures implemented in response to the Covid-19 pandemic, such as masking and social distancing.